- Report
- January 2024
- 126 Pages
Global
From €5317EUR$5,500USD£4,567GBP
- Report
- March 2024
- 192 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- February 2024
- 250 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,446GBP
- Report
- June 2023
- 233 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- January 2024
- 139 Pages
United States
From €3576EUR$3,699USD£3,072GBP
- Report
- May 2021
- 155 Pages
Global
From €1329EUR$1,375USD£1,142GBP
€2659EUR$2,750USD£2,284GBP
- Report
- December 2019
- 74 Pages
Global
From €955EUR$988USD£820GBP
€1909EUR$1,975USD£1,640GBP
- Report
- March 2024
- 121 Pages
Canada
From €3576EUR$3,699USD£3,072GBP
- Report
- September 2023
- 115 Pages
Japan
From €2609EUR$2,699USD£2,241GBP
Authorized generics are generic drugs that are produced and marketed by the same company that manufactures the brand-name version of the drug. This allows the company to maintain control over the production and distribution of the drug, while still providing a lower-cost alternative to the brand-name version. Authorized generics are typically priced lower than the brand-name version, but higher than other generic versions of the same drug.
The authorized generics market has grown in recent years as more companies have sought to capitalize on the cost savings associated with generic drugs. This has allowed companies to increase their market share and expand their product offerings.
Some of the major players in the authorized generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more